Funding for this research was provided by:
Deutsche Krebshilfe (Mildred-Scheel Postdoctoral Fellowship)
Deutsche Forschungsgemeinschaft (Postdoctoral Fellowship)
National Institutes of Health (K99LM011595)
Breast Cancer Research Foundation
Mary Kay Foundation
Breast Cancer Alliance
Dana-Farber/Harvard Cancer Center
Stand Up To Cancer
Entertainment Industry Foundation (SU2C-AACR-DT0209)
Text and Data Mining valid from 2019-11-19
Received: 10 October 2019
Accepted: 2 November 2019
First Online: 19 November 2019
Compliance with ethical standards
: PAK reports personal fees from Astra Zeneca, Merck, Pfizer, Tesaro and Bayer, outside the submitted work. UAM reports personal fees from Astra Zeneca, Myriad Genetics, Clovis, Merck, Eli Lilly, Mersana, Geneos, Fuji Film, 2X Oncology, Cerulean, Immunogen and Novartis, outside the submitted work. GMW reports grants from SU2C-AACRDT0209, Mary Kay Ash Fundation, Ovarian Cancer Research Foundation, Breast Cancer Alliance, Breast Cancer Research Foundation, NIH RO1 1R01CA226776-01 and Merck, during the conduct of the study. In addition, GMW has a patent application 14/348810, Compositions and Methods for the Treatment of proliferative diseases pending, and a patent US 20090258352 A1, Pin1 as a marker for abnormal cell growth licensed to Cell Signaling; R&D Systems. All other authors declare no conflicts.
: Informed consent was obtained from all individual participants included in the study.
: All procedures performed in this study were performed in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice. All patients provided written informed consent to allow the use of available biopsies for the analysis and research purposes of this study.